Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tir-c

TIR-C SIGNED

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TIR-C project word cloud

Explore the words cloud of the TIR-C project. It provides you a very rough idea of what is the project "TIR-C" about.

severe    itch    moderate    works    dermatitis    survey    regulatory    interfere    drafted    kols    feasibility    extremely    confirm    infected    pharma    80    vital    commercialisation    plan    poses    safe    atopic    affordable    disease    operate    pricing    eliminate    consistently    unsuitable    immune    escalation    children    inflammation    economic    excellent    communicated    contain    formulation    manufacturing    iia    blockbuster    dermatology    productivity    symptom    freedom    safety    clinical    damage    entirely    relives    tirmed    intravenously    steroids    societies    expenditures    profile    patient    topical    lesions    tir    psychological    costly    unmet    contract    prevent    health    approvals    burden    sleep    sufferers    quality    life    administrated    ab    cream    conduct    clinicians    diabetes    preparations    patients    readiness    defences    market    biologics    group    therapy    mind    anti    unresolved    symptoms    mechanism    mild    validate    consequently    persons    rate    ad    water    enormous    deprivation    steroid    action    skin    cro    trials    treatment    local    self   

Project "TIR-C" data sheet

The following table provides information about the project.

Coordinator		 TIRMED PHARMA AB 

Organization address
address: SPETS ALVIKSVAGEN 1
city: BROMMA
postcode: 16753
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIRMED PHARMA AB SE (BROMMA) coordinator 50˙000.00

Map

 Project objective

TIRmed pharma AB has developed a non-steroid cream that relives itch in Atopic Dermatitis (AD). Itch is an enormous, unresolved symptom in AD, induced by inflammation and skin damage. AD poses a significant burden on societies and patients’ quality of life due to itch, infected lesions, sleep deprivation, and consequently productivity loss, psychological health and treatment-associated expenditures. Persons affected by AD consistently rate AD management to be comparable to diabetes management. Our TIR-C cream doesn’t contain steroids and works through an entirely novel mechanism of action. The therapy has been developed with the largest patient group in mind; children. TIR-C has the potential to become a blockbuster in AD management as it has an excellent safety profile, is very affordable, is easy to self-apply (water-based), doesn’t interfere with vital immune defences and has the potential to prevent disease escalation. We target mild-to-moderate symptoms (80% of all AD sufferers), aiming to eliminate the need for intravenously administrated biologics. Biologics are not only extremely costly, but also associated with severe side effects, making them unsuitable for children. The unmet need for safe, topical anti-itch-treatment in persons with mild-to-moderate AD has been clearly communicated by leading contract research organizations, KOLs and clinicians within dermatology. TIR-C is at Technology Readiness Level 4 with established manufacturing and formulation processes and a clinical development plan drafted in collaboration with a leading CRO in dermatology. The proposed feasibility study will advance preparations for commercialisation by allowing us to confirm regulatory requirements needed for market approvals, validate pricing through a health-economic survey in the EU, identify a local CRO to conduct the planned phase I/IIa clinical trials and confirm Freedom to Operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIR-C" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIR-C" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More